个人中心 - 老虎社区

Diggydev

IP属地：未知

帖子 · 7帖子 · 7
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- DiggydevDiggydev
  ·2021-06-29
  Buying
  非常抱歉，此主贴已删除
  1,279 评论
  1
  分享
  举报
- DiggydevDiggydev
  ·2021-06-17
  Lookout for coming months when they release new products . Stock price will go up
  非常抱歉，此主贴已删除
  2,249 评论
  1
  分享
  举报
- DiggydevDiggydev
  ·2021-06-17
  Correct
  非常抱歉，此主贴已删除
  2,290 评论
  点赞
  分享
  举报
- DiggydevDiggydev
  ·2021-06-17
  Noice
  非常抱歉，此主贴已删除
  1,381 评论
  点赞
  分享
  举报
- DiggydevDiggydev
  ·2021-05-27
  Great ariticle, would you like to share it?
  非常抱歉，此主贴已删除
  2,369 评论
  点赞
  分享
  举报
- DiggydevDiggydev
  ·2021-04-29
  Beaut
  25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021<blockquote>25只被低估的股票，其盈利将在2021年超过新冠疫情前的水平</blockquote>
  SinceBarron’slast screened for European stocks whose earnings prospects may not be fully priced in,
  25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021<blockquote>25只被低估的股票，其盈利将在2021年超过新冠疫情前的水平</blockquote>
  1,253 评论
  1
  分享
  举报
- DiggydevDiggydev
  ·2021-04-23
  Thank you
  Why Ocugen Shares Skyrocketed Today<blockquote>为什么Ocugen股价今天飙升</blockquote>
  Ocugen Inc OCGN 42.92% shares soared 42.9% in the regular session and another 11% in the after-hours
  Why Ocugen Shares Skyrocketed Today<blockquote>为什么Ocugen股价今天飙升</blockquote>
  2,495 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3579486738960672","uuid":"3579486738960672","gmtCreate":1616392715024,"gmtModify":1616898019045,"name":"Diggydev","pinyin":"diggydev","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":150508531,"gmtCreate":1624919682523,"gmtModify":1633947156894,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Buying","listText":"Buying","text":"Buying","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150508531","repostId":"1124372919","repostType":2,"isVote":1,"tweetType":1,"viewCount":1279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161162700,"gmtCreate":1623911784700,"gmtModify":1634025957467,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Lookout for coming months when they release new products . Stock price will go up","listText":"Lookout for coming months when they release new products . Stock price will go up","text":"Lookout for coming months when they release new products . Stock price will go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161162700","repostId":"1152604932","repostType":4,"isVote":1,"tweetType":1,"viewCount":2249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163751510,"gmtCreate":1623894353230,"gmtModify":1634026258526,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Correct","listText":"Correct","text":"Correct","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163751510","repostId":"1152730219","repostType":4,"isVote":1,"tweetType":1,"viewCount":2290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163753711,"gmtCreate":1623894331633,"gmtModify":1634026259378,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Noice","listText":"Noice","text":"Noice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163753711","repostId":"1104709957","repostType":4,"isVote":1,"tweetType":1,"viewCount":1381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132986854,"gmtCreate":1622065767678,"gmtModify":1634184294104,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/132986854","repostId":"2138511164","repostType":4,"isVote":1,"tweetType":1,"viewCount":2369,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109588361,"gmtCreate":1619705028953,"gmtModify":1634210565807,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Beaut","listText":"Beaut","text":"Beaut","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109588361","repostId":"1161815718","repostType":4,"repost":{"id":"1161815718","kind":"news","pubTimestamp":1619685728,"share":"https://www.laohu8.com/m/news/1161815718?lang=zh_CN&edition=full","pubTime":"2021-04-29 16:42","market":"us","language":"en","title":"25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021<blockquote>25只被低估的股票，其盈利将在2021年超过新冠疫情前的水平</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161815718","media":"MarketWatch","summary":"SinceBarron’slast screened for European stocks whose earnings prospects may not be fully priced in, ","content":"<p>Since<i>Barron’s</i>last screened for European stocks whose earnings prospects may not be fully priced in, the pan-EuropeanStoxx 600has climbed to record highs despite much of the continent battling a third wave of Covid-19.</p><p><blockquote>自从<i>巴伦周刊</i>尽管欧洲大陆大部分地区正在与第三波Covid-19作斗争，但上次对其盈利前景可能尚未完全反映的欧洲股票进行筛选时，泛欧斯托克600指数已攀升至历史新高。</blockquote></p><p> The index is now up more than 10% year-to-date but there are signs that more gains could be ahead, with Europe’s economic recoveryyet to really get going. Initiallyslow vaccination rolloutsin many European countries are starting to gather pace, and the U.K. notably reopened large parts of the economy earlier this month.</p><p><blockquote>该指数今年迄今已上涨超过10%，但有迹象表明，随着欧洲经济复苏尚未真正开始，未来可能会有更多涨幅。许多欧洲国家最初缓慢的疫苗接种工作开始加快步伐，英国本月早些时候重新开放了大部分经济。</blockquote></p><p> Barclays’ European equity strategists devised a stock screen designed to find companies whose share price was lagging behind its earnings estimates. Their method screened for Stoxx 600 companies currently trading at least 5% below their levels at the end of 2019 and whose 2021 earnings per share, or EPS, estimates were above their pre-Covid 2019 EPS.</p><p><blockquote>巴克莱的欧洲股票策略师设计了一个股票屏幕，旨在寻找股价落后于其盈利预期的公司。他们的方法筛选了斯托克600指数公司，这些公司目前的交易价格比2019年底的水平至少低5%，并且其2021年每股收益(EPS)的预期高于新冠疫情爆发前的2019年EPS。</blockquote></p><p> “On this basis, consensus numbers suggest that the better earnings growth prospects of these stocks are not fully priced in, implying potentially attractive risk-reward ,” head of European equity strategy Emmanuel Cau said.</p><p><blockquote>欧洲股票策略主管Emmanuel Cau表示：“在此基础上，共识数据表明，这些股票更好的盈利增长前景并未完全反映在定价中，这意味着潜在的有吸引力的风险回报。”</blockquote></p><p> Following a similar approach,<i>Barron’s</i>screened the Stoxx 600 for stocks trading more than 10% below their levels at the end of 2019 and filtered for companies that trade for no more than 20 times forward earnings estimates. The screen used FactSet consensus estimates instead of Barclays consensus estimates. The companies must also have a market capitalization above $10 billion.</p><p><blockquote>按照类似的方法，<i>巴伦周刊</i>筛选了斯托克600指数中交易价格比2019年底水平低10%以上的股票，并筛选了交易价格不超过预期盈利预期20倍的公司。屏幕使用FactSet共识估计，而不是巴克莱共识估计。这些公司的市值还必须超过100亿美元。</blockquote></p><p> An earlier version of this screen at the end of Februarycontained 37 European companieswhose shares were more than 10% lower than their end-2019 levels.</p><p><blockquote>2月底的早期版本包含37家欧洲公司，其股价比2019年底的水平低10%以上。</blockquote></p><p> Since then, the index has jumped 6.8%, hitting record highs earlier this month. As a result the number of stocks in the screen dropped to 25 at the end of March and remains at 25 this time, with many departures down to rising share prices. However, there are still a number of stocks out there sitting below their 2019 levels but set to beat 2019 earnings this year—implying room for them to grow in the months ahead.</p><p><blockquote>自那以来，该指数已上涨6.8%，本月早些时候创下历史新高。结果，屏幕上的股票数量在3月底下降到25只，这次仍保持在25只，其中许多股票因股价上涨而下跌。然而，仍有许多股票低于2019年的水平，但今年的盈利将超过2019年——这意味着它们在未来几个月还有增长空间。</blockquote></p><p> Stocks Lagging EstimatesCompanies in the Stoxx 600 whose stock currently trade 10% or more below end-2019 levels but with 2021 earnings estimates above those of 2019, with a P/E ratio under 20.</p><p><blockquote>落后于预期的股票斯托克600指数中的公司目前股价比2019年底水平低10%或以上，但2021年盈利预期高于2019年，市盈率低于20。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/62565546aefb0d11006e4b97a5746aea\" tg-width=\"930\" tg-height=\"736\"><img src=\"https://static.tigerbbs.com/b281e399475bb5ee78464c4d57b43c14\" tg-width=\"932\" tg-height=\"706\"></p><p><blockquote></blockquote></p><p> Four stocks have exited the screen: French telecoms companyOrange,insurance firmAxa,French defense groupThalesand Swiss-based Coke bottlerCoca-Cola HBC.&nbsp;Axa, Coca-Cola HBC and Thales have all seen their share prices rise in the past month, leading to their exit. Orange stock still remains 21% lower than it was at the end of 2019, but the telecoms giant’s 2021 EPS estimate has fallen in recent weeks, and is now expected to be flat compared to 2019.</p><p><blockquote>四只股票退出了屏幕：法国电信公司Orange、保险公司Maxa、法国国防集团泰雷兹和瑞士可口可乐装瓶商可口可乐HBC。安盛、可口可乐HBC和泰雷兹的股价在过去一个月都上涨，导致它们退出。Orange股价仍比2019年底低21%，但这家电信巨头对2021年每股收益的预期在最近几周有所下降，目前预计与2019年持平。</blockquote></p><p> Four companies have entered the screen: French insurerCNP Assurances,Swedish telecoms companyTelia,Swiss bankCredit Suisseand Norwegian oil-and-gas producerAker BP.Shares in both CNP and Telia have slipped over the past month to more than 10% lower than their end-2019 levels. Credit Suisse features because analysts now forecast the bank’s 2021 EPS to beat that of 2019, while Aker BP’s market value has risen above $10 billion for its first inclusion in the screen.</p><p><blockquote>四家公司进入了屏幕：法国保险公司CNP Assurances、瑞典电信公司Telia、瑞士银行Credit Suisse和挪威石油和天然气生产商Raker BP。过去一个月，CNP和Telia的股价均较2019年底的水平下跌10%以上。瑞士信贷之所以引人注目，是因为分析师现在预测该银行2021年的每股收益将超过2019年，而Aker BP的市值首次出现在屏幕上，已升至100亿美元以上。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021<blockquote>25只被低估的股票，其盈利将在2021年超过新冠疫情前的水平</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021<blockquote>25只被低估的股票，其盈利将在2021年超过新冠疫情前的水平</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-04-29 16:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Since<i>Barron’s</i>last screened for European stocks whose earnings prospects may not be fully priced in, the pan-EuropeanStoxx 600has climbed to record highs despite much of the continent battling a third wave of Covid-19.</p><p><blockquote>自从<i>巴伦周刊</i>尽管欧洲大陆大部分地区正在与第三波Covid-19作斗争，但上次对其盈利前景可能尚未完全反映的欧洲股票进行筛选时，泛欧斯托克600指数已攀升至历史新高。</blockquote></p><p> The index is now up more than 10% year-to-date but there are signs that more gains could be ahead, with Europe’s economic recoveryyet to really get going. Initiallyslow vaccination rolloutsin many European countries are starting to gather pace, and the U.K. notably reopened large parts of the economy earlier this month.</p><p><blockquote>该指数今年迄今已上涨超过10%，但有迹象表明，随着欧洲经济复苏尚未真正开始，未来可能会有更多涨幅。许多欧洲国家最初缓慢的疫苗接种工作开始加快步伐，英国本月早些时候重新开放了大部分经济。</blockquote></p><p> Barclays’ European equity strategists devised a stock screen designed to find companies whose share price was lagging behind its earnings estimates. Their method screened for Stoxx 600 companies currently trading at least 5% below their levels at the end of 2019 and whose 2021 earnings per share, or EPS, estimates were above their pre-Covid 2019 EPS.</p><p><blockquote>巴克莱的欧洲股票策略师设计了一个股票屏幕，旨在寻找股价落后于其盈利预期的公司。他们的方法筛选了斯托克600指数公司，这些公司目前的交易价格比2019年底的水平至少低5%，并且其2021年每股收益(EPS)的预期高于新冠疫情爆发前的2019年EPS。</blockquote></p><p> “On this basis, consensus numbers suggest that the better earnings growth prospects of these stocks are not fully priced in, implying potentially attractive risk-reward ,” head of European equity strategy Emmanuel Cau said.</p><p><blockquote>欧洲股票策略主管Emmanuel Cau表示：“在此基础上，共识数据表明，这些股票更好的盈利增长前景并未完全反映在定价中，这意味着潜在的有吸引力的风险回报。”</blockquote></p><p> Following a similar approach,<i>Barron’s</i>screened the Stoxx 600 for stocks trading more than 10% below their levels at the end of 2019 and filtered for companies that trade for no more than 20 times forward earnings estimates. The screen used FactSet consensus estimates instead of Barclays consensus estimates. The companies must also have a market capitalization above $10 billion.</p><p><blockquote>按照类似的方法，<i>巴伦周刊</i>筛选了斯托克600指数中交易价格比2019年底水平低10%以上的股票，并筛选了交易价格不超过预期盈利预期20倍的公司。屏幕使用FactSet共识估计，而不是巴克莱共识估计。这些公司的市值还必须超过100亿美元。</blockquote></p><p> An earlier version of this screen at the end of Februarycontained 37 European companieswhose shares were more than 10% lower than their end-2019 levels.</p><p><blockquote>2月底的早期版本包含37家欧洲公司，其股价比2019年底的水平低10%以上。</blockquote></p><p> Since then, the index has jumped 6.8%, hitting record highs earlier this month. As a result the number of stocks in the screen dropped to 25 at the end of March and remains at 25 this time, with many departures down to rising share prices. However, there are still a number of stocks out there sitting below their 2019 levels but set to beat 2019 earnings this year—implying room for them to grow in the months ahead.</p><p><blockquote>自那以来，该指数已上涨6.8%，本月早些时候创下历史新高。结果，屏幕上的股票数量在3月底下降到25只，这次仍保持在25只，其中许多股票因股价上涨而下跌。然而，仍有许多股票低于2019年的水平，但今年的盈利将超过2019年——这意味着它们在未来几个月还有增长空间。</blockquote></p><p> Stocks Lagging EstimatesCompanies in the Stoxx 600 whose stock currently trade 10% or more below end-2019 levels but with 2021 earnings estimates above those of 2019, with a P/E ratio under 20.</p><p><blockquote>落后于预期的股票斯托克600指数中的公司目前股价比2019年底水平低10%或以上，但2021年盈利预期高于2019年，市盈率低于20。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/62565546aefb0d11006e4b97a5746aea\" tg-width=\"930\" tg-height=\"736\"><img src=\"https://static.tigerbbs.com/b281e399475bb5ee78464c4d57b43c14\" tg-width=\"932\" tg-height=\"706\"></p><p><blockquote></blockquote></p><p> Four stocks have exited the screen: French telecoms companyOrange,insurance firmAxa,French defense groupThalesand Swiss-based Coke bottlerCoca-Cola HBC.&nbsp;Axa, Coca-Cola HBC and Thales have all seen their share prices rise in the past month, leading to their exit. Orange stock still remains 21% lower than it was at the end of 2019, but the telecoms giant’s 2021 EPS estimate has fallen in recent weeks, and is now expected to be flat compared to 2019.</p><p><blockquote>四只股票退出了屏幕：法国电信公司Orange、保险公司Maxa、法国国防集团泰雷兹和瑞士可口可乐装瓶商可口可乐HBC。安盛、可口可乐HBC和泰雷兹的股价在过去一个月都上涨，导致它们退出。Orange股价仍比2019年底低21%，但这家电信巨头对2021年每股收益的预期在最近几周有所下降，目前预计与2019年持平。</blockquote></p><p> Four companies have entered the screen: French insurerCNP Assurances,Swedish telecoms companyTelia,Swiss bankCredit Suisseand Norwegian oil-and-gas producerAker BP.Shares in both CNP and Telia have slipped over the past month to more than 10% lower than their end-2019 levels. Credit Suisse features because analysts now forecast the bank’s 2021 EPS to beat that of 2019, while Aker BP’s market value has risen above $10 billion for its first inclusion in the screen.</p><p><blockquote>四家公司进入了屏幕：法国保险公司CNP Assurances、瑞典电信公司Telia、瑞士银行Credit Suisse和挪威石油和天然气生产商Raker BP。过去一个月，CNP和Telia的股价均较2019年底的水平下跌10%以上。瑞士信贷之所以引人注目，是因为分析师现在预测该银行2021年的每股收益将超过2019年，而Aker BP的市值首次出现在屏幕上，已升至100亿美元以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/articles/25-undervalued-stocks-with-earnings-set-to-beat-pre-covid-levels-in-2021-51619641093?mod=mw_latestnews\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/articles/25-undervalued-stocks-with-earnings-set-to-beat-pre-covid-levels-in-2021-51619641093?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161815718","content_text":"SinceBarron’slast screened for European stocks whose earnings prospects may not be fully priced in, the pan-EuropeanStoxx 600has climbed to record highs despite much of the continent battling a third wave of Covid-19.\nThe index is now up more than 10% year-to-date but there are signs that more gains could be ahead, with Europe’s economic recoveryyet to really get going. Initiallyslow vaccination rolloutsin many European countries are starting to gather pace, and the U.K. notably reopened large parts of the economy earlier this month.\nBarclays’ European equity strategists devised a stock screen designed to find companies whose share price was lagging behind its earnings estimates. Their method screened for Stoxx 600 companies currently trading at least 5% below their levels at the end of 2019 and whose 2021 earnings per share, or EPS, estimates were above their pre-Covid 2019 EPS.\n“On this basis, consensus numbers suggest that the better earnings growth prospects of these stocks are not fully priced in, implying potentially attractive risk-reward ,” head of European equity strategy Emmanuel Cau said.\nFollowing a similar approach,Barron’sscreened the Stoxx 600 for stocks trading more than 10% below their levels at the end of 2019 and filtered for companies that trade for no more than 20 times forward earnings estimates. The screen used FactSet consensus estimates instead of Barclays consensus estimates. The companies must also have a market capitalization above $10 billion.\nAn earlier version of this screen at the end of Februarycontained 37 European companieswhose shares were more than 10% lower than their end-2019 levels.\nSince then, the index has jumped 6.8%, hitting record highs earlier this month. As a result the number of stocks in the screen dropped to 25 at the end of March and remains at 25 this time, with many departures down to rising share prices. However, there are still a number of stocks out there sitting below their 2019 levels but set to beat 2019 earnings this year—implying room for them to grow in the months ahead.\nStocks Lagging EstimatesCompanies in the Stoxx 600 whose stock currently trade 10% or more below end-2019 levels but with 2021 earnings estimates above those of 2019, with a P/E ratio under 20.\n\nFour stocks have exited the screen: French telecoms companyOrange,insurance firmAxa,French defense groupThalesand Swiss-based Coke bottlerCoca-Cola HBC. Axa, Coca-Cola HBC and Thales have all seen their share prices rise in the past month, leading to their exit. Orange stock still remains 21% lower than it was at the end of 2019, but the telecoms giant’s 2021 EPS estimate has fallen in recent weeks, and is now expected to be flat compared to 2019.\nFour companies have entered the screen: French insurerCNP Assurances,Swedish telecoms companyTelia,Swiss bankCredit Suisseand Norwegian oil-and-gas producerAker BP.Shares in both CNP and Telia have slipped over the past month to more than 10% lower than their end-2019 levels. Credit Suisse features because analysts now forecast the bank’s 2021 EPS to beat that of 2019, while Aker BP’s market value has risen above $10 billion for its first inclusion in the screen.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376472371,"gmtCreate":1619145561493,"gmtModify":1634288206568,"author":{"id":"3579486738960672","authorId":"3579486738960672","name":"Diggydev","avatar":"https://static.tigerbbs.com/d06f5986ff1dbc96ab8c8fccfad66cb9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579486738960672","idStr":"3579486738960672"},"themes":[],"htmlText":"Thank you&nbsp;","listText":"Thank you&nbsp;","text":"Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/376472371","repostId":"1137961906","repostType":4,"repost":{"id":"1137961906","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1619145390,"share":"https://www.laohu8.com/m/news/1137961906?lang=zh_CN&edition=full","pubTime":"2021-04-23 10:36","market":"us","language":"en","title":"Why Ocugen Shares Skyrocketed Today<blockquote>为什么Ocugen股价今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137961906","media":"Benzinga","summary":"Ocugen Inc OCGN 42.92% shares soared 42.9% in the regular session and another 11% in the after-hours","content":"<p><b>Ocugen Inc</b>&nbsp;OCGN 42.92%&nbsp;shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday.</p><p><blockquote><b>Ocugen公司</b>OCGN 42.92%股价在常规交易中飙升42.9%，在周四盘后交易中又飙升11%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/a5596cd8cf4db1a7bb5b759d4f269eeb\" tg-width=\"1022\" tg-height=\"459\"></p><p><blockquote></blockquote></p><p><b>What Happened:</b>&nbsp;The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.</p><p><blockquote><b>发生了什么：</b>在Ocugen合伙人宣布积极的临床数据以及Roth Capital分析师Zegbeh Jallah采取看涨立场后，该股飙升，Zegbeh Jallah对该股给予买入评级，12个月目标价为10美元。</blockquote></p><p>Earlier, on Wednesday, Ocugen’s co-development partner Bharat Biotech said that the second interim analysis of Phase 3 of Covaxin, a COVID-19 vaccine candidate, shows itdemonstrated 78% efficiencyin mild, moderate, and severe disease.</p><p><blockquote>周三早些时候，Ocugen的共同开发合作伙伴Bharat Biotech表示，对COVID-19候选疫苗科瓦克辛3期的第二次中期分析显示，其对轻度、中度和重度疾病的有效率为78%。</blockquote></p><p>The vaccine is reportedly 100% effective against severe forms of viral illness.</p><p><blockquote>据报道，这种疫苗对严重的病毒性疾病100%有效。</blockquote></p><p>In a note, Jallah said that Ocugen has sufficient information to support the filing of an Emergency Use Authorization application in the United States.</p><p><blockquote>Jallah在一份说明中表示，Ocugen有足够的信息支持在美国提交紧急使用授权申请。</blockquote></p><p>“If granted, this could lead to a significant revenue generating opportunity for Ocugen,” wrote the analyst.</p><p><blockquote>这位分析师写道：“如果获得批准，这可能会为Ocugen带来巨大的创收机会。”</blockquote></p><p>Jallah said that management has confirmed plans to make Covaxin available in the U.S.</p><p><blockquote>贾拉表示，管理层已确认在美国提供科瓦克辛的计划。</blockquote></p><p>The vaccine’s initial batches will undergo test and release at a U.S. facility approved by the Food and Drug Administration, as per Jallah.</p><p><blockquote>根据Jallah的说法，该疫苗的第一批将在美国食品药品监督管理局批准的设施中进行测试和发布。</blockquote></p><p>Meanwhile, Bharat Biotech isramping up manufacturingto produce 700 million COVID-19 vaccine doses annually.</p><p><blockquote>与此同时，Bharat Biotech正在加大生产力度，每年生产7亿剂COVID-19疫苗。</blockquote></p><p>Earlier in the month, it was reported that Ocugen plans to sell100 million Covaxin dosesin the U.S.</p><p><blockquote>本月早些时候，有报道称Ocugen计划在美国销售1亿剂科瓦克辛疫苗。</blockquote></p><p><b>Price Action:</b>&nbsp;Ocugen shares closed 42.92% higher at $9.29 on Thursday and rose another almost 11% to $10.31 in the after-hours trading.</p><p><blockquote><b>价格走势：</b>Ocugen股价周四收盘上涨42.92%，至9.29美元，在盘后交易中又上涨近11%，至10.31美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Ocugen Shares Skyrocketed Today<blockquote>为什么Ocugen股价今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Ocugen Shares Skyrocketed Today<blockquote>为什么Ocugen股价今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-04-23 10:36</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Ocugen Inc</b>&nbsp;OCGN 42.92%&nbsp;shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday.</p><p><blockquote><b>Ocugen公司</b>OCGN 42.92%股价在常规交易中飙升42.9%，在周四盘后交易中又飙升11%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/a5596cd8cf4db1a7bb5b759d4f269eeb\" tg-width=\"1022\" tg-height=\"459\"></p><p><blockquote></blockquote></p><p><b>What Happened:</b>&nbsp;The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.</p><p><blockquote><b>发生了什么：</b>在Ocugen合伙人宣布积极的临床数据以及Roth Capital分析师Zegbeh Jallah采取看涨立场后，该股飙升，Zegbeh Jallah对该股给予买入评级，12个月目标价为10美元。</blockquote></p><p>Earlier, on Wednesday, Ocugen’s co-development partner Bharat Biotech said that the second interim analysis of Phase 3 of Covaxin, a COVID-19 vaccine candidate, shows itdemonstrated 78% efficiencyin mild, moderate, and severe disease.</p><p><blockquote>周三早些时候，Ocugen的共同开发合作伙伴Bharat Biotech表示，对COVID-19候选疫苗科瓦克辛3期的第二次中期分析显示，其对轻度、中度和重度疾病的有效率为78%。</blockquote></p><p>The vaccine is reportedly 100% effective against severe forms of viral illness.</p><p><blockquote>据报道，这种疫苗对严重的病毒性疾病100%有效。</blockquote></p><p>In a note, Jallah said that Ocugen has sufficient information to support the filing of an Emergency Use Authorization application in the United States.</p><p><blockquote>Jallah在一份说明中表示，Ocugen有足够的信息支持在美国提交紧急使用授权申请。</blockquote></p><p>“If granted, this could lead to a significant revenue generating opportunity for Ocugen,” wrote the analyst.</p><p><blockquote>这位分析师写道：“如果获得批准，这可能会为Ocugen带来巨大的创收机会。”</blockquote></p><p>Jallah said that management has confirmed plans to make Covaxin available in the U.S.</p><p><blockquote>贾拉表示，管理层已确认在美国提供科瓦克辛的计划。</blockquote></p><p>The vaccine’s initial batches will undergo test and release at a U.S. facility approved by the Food and Drug Administration, as per Jallah.</p><p><blockquote>根据Jallah的说法，该疫苗的第一批将在美国食品药品监督管理局批准的设施中进行测试和发布。</blockquote></p><p>Meanwhile, Bharat Biotech isramping up manufacturingto produce 700 million COVID-19 vaccine doses annually.</p><p><blockquote>与此同时，Bharat Biotech正在加大生产力度，每年生产7亿剂COVID-19疫苗。</blockquote></p><p>Earlier in the month, it was reported that Ocugen plans to sell100 million Covaxin dosesin the U.S.</p><p><blockquote>本月早些时候，有报道称Ocugen计划在美国销售1亿剂科瓦克辛疫苗。</blockquote></p><p><b>Price Action:</b>&nbsp;Ocugen shares closed 42.92% higher at $9.29 on Thursday and rose another almost 11% to $10.31 in the after-hours trading.</p><p><blockquote><b>价格走势：</b>Ocugen股价周四收盘上涨42.92%，至9.29美元，在盘后交易中又上涨近11%，至10.31美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137961906","content_text":"Ocugen Inc OCGN 42.92% shares soared 42.9% in the regular session and another 11% in the after-hours session on Thursday.What Happened: The shares surged following positive clinical data announced by a partner of Ocugen and a bullish stance taken by Roth Capital analyst Zegbeh Jallah who has a Buy rating on the stock and a 12-month price target of $10.Earlier, on Wednesday, Ocugen’s co-development partner Bharat Biotech said that the second interim analysis of Phase 3 of Covaxin, a COVID-19 vaccine candidate, shows itdemonstrated 78% efficiencyin mild, moderate, and severe disease.The vaccine is reportedly 100% effective against severe forms of viral illness.In a note, Jallah said that Ocugen has sufficient information to support the filing of an Emergency Use Authorization application in the United States.“If granted, this could lead to a significant revenue generating opportunity for Ocugen,” wrote the analyst.Jallah said that management has confirmed plans to make Covaxin available in the U.S.The vaccine’s initial batches will undergo test and release at a U.S. facility approved by the Food and Drug Administration, as per Jallah.Meanwhile, Bharat Biotech isramping up manufacturingto produce 700 million COVID-19 vaccine doses annually.Earlier in the month, it was reported that Ocugen plans to sell100 million Covaxin dosesin the U.S.Price Action: Ocugen shares closed 42.92% higher at $9.29 on Thursday and rose another almost 11% to $10.31 in the after-hours trading.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}